Research finds insufficient data transparency for FDA-cleared AI devices in Alzheimer’s imaging, raising bias and generalizability concerns.
Key Details
- 124 AI/ML-based devices for Alzheimer's disease and related dementias (ADRD) were FDA-authorized between January 2015 and December 2024.
- 291.7% (22/24) were cleared via the 510(k) pathway; 8.3% (2/24) through de novo classification.
- 3For 12 devices, there was no info on training or validation data in FDA summaries or peer-reviewed articles.
- 4Only 2 FDA summaries (8.3%) included external validation data; 10 peer-reviewed articles (41.7%) provided such data.
- 5Reporting of disease status, age, sex, race, and ethnicity was rare across most devices; demographic transparency was lacking.
- 6Most devices (21) were reviewed by radiology panels and primarily involved MRI and PET imaging.
Why It Matters
Transparent disclosure of training and validation data, especially demographic details, is vital for assessing bias and clinical accuracy in AI-based imaging devices. Without sufficient data transparency, there is uncertainty about the generalizability and safety of these AI tools in real-world, diverse patient populations.
Source
AuntMinnie
Related News
•AuntMinnie
Study: Computer Vision Models Best LLMs in Chest CT Breast Abnormality Detection
Computer vision models (CVMs) surpass large language models (LLMs) in accurately labeling incidental breast abnormalities on chest CT scans.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•AuntMinnie
Deep Learning Models Rival Radiologists for Pancreatic Cancer Detection on CT
Deep-learning models achieved comparable or superior accuracy to experienced radiologists in detecting pancreatic cancer on CT scans, especially for small tumors.